- 4.6Impact Factor
- 8.6CiteScore
- 17 daysTime to First Decision
Bioactive Molecules as Multidrug Resistance Modulators
Special Issue Information
Dear Colleagues,
Cancer therapy remains a major challenge, particularly in cancers exhibiting multidrug resistance (MDR). Cancers with an MDR phenotype exhibit cross-resistance to a wide range of anticancer drugs, which limits the treatment of many cancer patients. This Special Issue of Molecules aims to present a collection of original research articles and review articles on bioactive novel compounds or small molecules (chemically synthesized or of natural origin), or repurposed drugs, that act on multidrug resistance mechanisms. Papers on molecules that improve drug response to cancer therapy or novel mechanisms of drug resistance to antitumor drugs will be also considered.
Dr. Cristina P.R. Xavier
Prof. Dr. M. Helena Vasconcelos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer drug resistance
- multidrug resistance
- anticancer compounds
- repurposed drugs
- drug resistance mechanisms in cancer
- natural and synthetic products to counteract cancer drug resistance
- cell death and apoptosis
- cancer cell proliferation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.